Immunizations for Respiratory Virus Season

Katie Mahuron, RN – Adult Coordinator
Agenda – 1/11/2024

- Influenza Vaccine
- COVID-19 Vaccine
- RSV Vaccine and Therapeutics

Contact Information
- Ordering, vaccine storage and handling, vaccine-specific information: AHS.VDHImmunizationProgram@vermont.gov
- Immunization registry and reporting questions: IMR@vermont.gov
Influenza Vaccine

- Recommended for everyone 6 months and up
- Not too late to be vaccinated
  - 0-4 yrs. – 38 percent vaccinated statewide
  - 5-12 yrs. – 33 percent vaccinated statewide
- Access in pharmacies or provider offices
- Pharmacies can vaccinate children aged 3 years and older
  - Medicaid does not cover cost of flu vaccine if administered in pharmacies

Vermont Department of Health
COVID-19 Vaccine

- Everyone 6 months and older needs the updated 2023-2024 Formula COVID-19 vaccine
- Number of doses needed depends on age and previous doses received.
- Not too late to be vaccinated.
  - 0-4 yrs. – 14 percent vaccinated
  - 5-12 yrs. – 14 percent vaccinated
- Access vaccine in pharmacies or primary care provider offices
- Pharmacies can vaccinate children aged 3 years and older
  - Medicaid will cover cost of COVID-19 vaccine administered in pharmacies
COVID-19 Vaccine Recommendations for People Not Moderately or Severely Immunocompromised

- **Recommended updated (2023-2024) Formula Covid-19 vaccines for people who are NOT moderately or severely immunocompromised—October 12, 2023 (cdc.gov)**
- **Recommend updated (2023-2024 Formula) COVID-19 vaccines for people who are moderately or severely immunocompromised (cdc.gov)**
RSV Products

- New products available this year for protection against severe RSV
  - Monoclonal antibody product for infants
  - Vaccine for pregnant individuals (to protect infants)
  - Vaccine for older adults (60 yrs. +)

- Rocky rollout of products, especially those for protecting infants

<table>
<thead>
<tr>
<th>Who Does It Protect?</th>
<th>Type of Product</th>
<th>Is It for Everyone in Group?</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adults 60 and over</td>
<td>RSV vaccine</td>
<td>Talk to your doctor first</td>
</tr>
<tr>
<td>Babies</td>
<td>RSV antibody given to baby</td>
<td>All infants entering or born during RSV season. Small group of older babies for second season.</td>
</tr>
<tr>
<td>OR</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Babies</td>
<td>RSV vaccine given during pregnancy</td>
<td>Can get if you are 32-36 weeks pregnant during September-January</td>
</tr>
</tbody>
</table>
Nirsevimab (Beyfortus) – monoclonal antibody

Who should receive the immunization?
• Universal recommendation for infants 8 months and younger
• Recommended for select group of high-risk infants 8-19 months

Where can it be accessed?
• Access in birthing hospitals and provider offices
• Supply has been very limited
Nirsevimab (Beyfortus) supply update

- Manufacturer produced enough product for approximately 30% of the birth cohort
- Rolled out in early October and immediately ordering paused as demand exceeded supply
- CDC released prioritization recommendations prioritizing infants under 6 months and high-risk infants under 8 months
  - CDC [rescinded prioritization recommendations](#) January 5, 2024
RSV Vaccine for Pregnant Individuals

- Available now in pharmacies:
  - Walgreens, Shaw’s Osco, Hannaford, CVS, Costco and UVMMC pharmacies

- Have heard some individuals have been turned away
  - Pharmacy must have the Abrysvo vaccine
  - Medicaid requires prior authorization for RSV vaccine for pregnant people
  - Private insurers may also require prior authorization
# RSV Product Overview

<table>
<thead>
<tr>
<th>Population</th>
<th>Product</th>
<th>Dosage</th>
<th>Timeline for Administration</th>
<th>What else should I know?</th>
</tr>
</thead>
<tbody>
<tr>
<td>Infants 8 months and younger</td>
<td>Nirsevimab (Beyfortus) monoclonal antibody product</td>
<td>Weight-based: 50 mg: &lt;5 kg 100 mg: ≥5 kg</td>
<td>RSV season only (October 1 – March 31)</td>
<td>Should not receive if birthed by someone who received the RSV vaccine during pregnancy (unless has not been 14 days since vaccination)</td>
</tr>
<tr>
<td>Infants 8 - 19 months* AND high-risk</td>
<td>Nirsevimab (Beyfortus): monoclonal antibody product</td>
<td>200 mg</td>
<td>RSV season only (October 1 – March 31)</td>
<td></td>
</tr>
<tr>
<td>*8 months, 1 day – 19 months, 30 days</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pregnant individuals</td>
<td>Abrysvo (Pfizer) vaccine</td>
<td>0.5 mL</td>
<td>September 1 – January 31; 32 –36 weeks* gestation</td>
<td>Available in pharmacies</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>*32 weeks 0 days – 36 weeks 6 days</td>
<td></td>
</tr>
<tr>
<td>Adults 60+</td>
<td>Abrysvo (Pfizer) &amp; Arexvy (GSK) vaccine</td>
<td>0.5 mL</td>
<td>Can be administered at any time throughout year</td>
<td>VAVP supply for 60-64 yrs. only</td>
</tr>
</tbody>
</table>
Questions
Thank you!

Let’s stay in touch.

AHS.VDHImmunizationProgram@vermont.gov
healthvermont.org
@healthvermont